Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non–small-cell lung cancer
PURPOSE Heterogeneity in tumor mutational burden (TMB) quantification across
sequencing platforms limits the application and further study of this potential biomarker of …
sequencing platforms limits the application and further study of this potential biomarker of …
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
PA Konstantinopoulos, AABA da Costa… - Nature …, 2021 - nature.com
In a trial of patients with high grade serous ovarian cancer (HGSOC), addition of the ATR
inhibitor berzosertib to gemcitabine improved progression free survival (PFS) compared to …
inhibitor berzosertib to gemcitabine improved progression free survival (PFS) compared to …
Assessment of deep natural language processing in ascertaining oncologic outcomes from radiology reports
KL Kehl, H Elmarakeby, M Nishino… - JAMA …, 2019 - jamanetwork.com
Importance A rapid learning health care system for oncology will require scalable methods
for extracting clinical end points from electronic health records (EHRs). Outside of clinical …
for extracting clinical end points from electronic health records (EHRs). Outside of clinical …
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
We conducted next-generation DNA sequencing on 335 biliary tract cancers and
characterized the genomic landscape by anatomic site within the biliary tree. In addition to …
characterized the genomic landscape by anatomic site within the biliary tree. In addition to …
Targeted genomic profiling reveals recurrent KRAS mutations in mesonephric-like adenocarcinomas of the female genital tract
J Mirkovic, M McFarland, E Garcia… - The American Journal …, 2018 - journals.lww.com
Mesonephric adenocarcinoma most commonly arises in the cervix and is presumed to be
derived from normal or hyperplastic mesonephric remnants. It is characterized by recurrent …
derived from normal or hyperplastic mesonephric remnants. It is characterized by recurrent …
Detection of mutations in Barrett's esophagus before progression to high-grade dysplasia or adenocarcinoma
MD Stachler, ND Camarda, C Deitrick, A Kim… - Gastroenterology, 2018 - Elsevier
Background & Aims Barrett's esophagus (BE) is the greatest risk factor for esophageal
adenocarcinoma (EAC), but only a small proportion of patients with BE develop cancer …
adenocarcinoma (EAC), but only a small proportion of patients with BE develop cancer …
Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites
Purpose: The purpose of this study is to characterize the mutational landscape across the
spectrum of urothelial carcinoma (UC) to identify mutational features and potential …
spectrum of urothelial carcinoma (UC) to identify mutational features and potential …
Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma
How the glioma immune microenvironment fosters tumorigenesis remains incompletely
defined. Here, we use single-cell RNA-sequencing and multiplexed tissue-imaging to …
defined. Here, we use single-cell RNA-sequencing and multiplexed tissue-imaging to …
[HTML][HTML] Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer
Background Programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) is the
primary clinically-available biomarker of response to immunotherapy in non-small-cell lung …
primary clinically-available biomarker of response to immunotherapy in non-small-cell lung …
Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset
To accelerate cancer research that correlates biomarkers with clinical endpoints, methods
are needed to ascertain outcomes from electronic health records at scale. Here, we train …
are needed to ascertain outcomes from electronic health records at scale. Here, we train …